In a report released on November 14, Marc Goodman from SVB Securities maintained a Buy rating on Eliem Therapeutics (ELYM – Research Report), with a price target of $4.00. The company’s shares closed yesterday at $3.01.
According to TipRanks, Goodman is an analyst with an average return of -1.7% and a 42.72% success rate. Goodman covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Axsome Therapeutics, and Satsuma Pharmaceuticals.
Eliem Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $5.00, a 66.11% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.
See the top stocks recommended by analysts >>
Based on Eliem Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $14.6 million. In comparison, last year the company had a GAAP net loss of $8.72 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.
Read More on ELYM:
